Jill Gilbert

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. pmc Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
    Jill Gilbert
    Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Head Neck 35:942-8. 2013
  2. pmc A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck
    Jill Gilbert
    Vanderbilt University School of Medicine, Nashville, TN, USA
    Clin Cancer Res 18:1735-42. 2012
  3. doi request reprint Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene
    Jill Gilbert
    Department of Medicine, Hematology Oncology Vanderbilt University School of Medicine Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee, USA
    Head Neck 34:359-64. 2012
  4. doi request reprint Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer
    Jill Gilbert
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Cancer 118:1007-13. 2012
  5. doi request reprint Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232, USA
    Cancer 113:186-92. 2008
  6. ncbi request reprint Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Adv Hematol Oncol 4:611-9. 2006
  7. doi request reprint Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health
    Emily Cooperstein
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Head Neck 34:797-804. 2012
  8. ncbi request reprint Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life
    Jie Deng
    School of Nursing, Vanderbilt University, Nashville, Tennessee 37240, USA
    Head Neck 35:1026-35. 2013
  9. pmc Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
    Athanassios Argiris
    Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, MC8232, Zeller Building, 4th Floor, Room Z418, San Antonio, TX 78229, USA
    J Clin Oncol 31:1405-14. 2013
  10. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010

Detail Information

Publications29

  1. pmc Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
    Jill Gilbert
    Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Head Neck 35:942-8. 2013
    ..Irinotecan demonstrates single-agent activity in head and neck cancer but activates NF-κB, promoting cell survival and resistance. Bortezomib is a proteasome inhibitor that inactivates NF-κB...
  2. pmc A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck
    Jill Gilbert
    Vanderbilt University School of Medicine, Nashville, TN, USA
    Clin Cancer Res 18:1735-42. 2012
    ..We also sought evidence of biologic activity of erlotinib alone using serial 18-FDG positron emission tomography (PET) imaging...
  3. doi request reprint Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene
    Jill Gilbert
    Department of Medicine, Hematology Oncology Vanderbilt University School of Medicine Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee, USA
    Head Neck 34:359-64. 2012
    ..The purpose of this study was to show the evaluated depression in patients with head and neck cancer and a possible association with the 5-HTTLPR...
  4. doi request reprint Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer
    Jill Gilbert
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Cancer 118:1007-13. 2012
    ..This phase 2 trial evaluated the tolerability and clinical efficacy of the combination of oxaliplatin and pemetrexed as an induction chemotherapy regimen in locally advanced head and neck squamous cell carcinoma (HNSCC)...
  5. doi request reprint Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232, USA
    Cancer 113:186-92. 2008
    ..Thus, new agents are needed. The authors report the results of a phase II trial of irinotecan and cisplatin in patients with metastatic or recurrent HNC...
  6. ncbi request reprint Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Adv Hematol Oncol 4:611-9. 2006
    ..The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN...
  7. doi request reprint Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health
    Emily Cooperstein
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Head Neck 34:797-804. 2012
    ..We report development of an oral health outcome subscale for the Vanderbilt Head and Neck Symptom Survey (VHNSS)...
  8. ncbi request reprint Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life
    Jie Deng
    School of Nursing, Vanderbilt University, Nashville, Tennessee 37240, USA
    Head Neck 35:1026-35. 2013
    ..The purpose of this study was to examine the associations among severity of internal and external lymphedema, symptoms, functional status, and QOL in patients with head and neck cancer...
  9. pmc Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
    Athanassios Argiris
    Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, MC8232, Zeller Building, 4th Floor, Room Z418, San Antonio, TX 78229, USA
    J Clin Oncol 31:1405-14. 2013
    ..We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN)...
  10. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
    ....
  11. doi request reprint Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation
    Barbara A Murphy
    Department of Medicine, Vanderbilt University Medical Center, USA
    Head Neck 32:26-37. 2010
    ....
  12. doi request reprint Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer
    Roberto Diaz
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 77:468-76. 2010
    ....
  13. doi request reprint Evolution of clinical trials in head and neck cancer
    Eddy S Yang
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232 5671, USA
    Crit Rev Oncol Hematol 71:29-42. 2009
    ..Emerging new technologies such as intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) will also be reviewed. Functional assessments and quality of life issues will be addressed...
  14. ncbi request reprint Symptom control issues and supportive care of patients with head and neck cancers
    Barbara A Murphy
    Vanderbilt University Medical Center, Division of Hematology Oncology, Nashville, TN 37232, USA
    Clin Adv Hematol Oncol 5:807-22. 2007
    ..Additionally, the pretreatment and during-treatment evaluation of dental health, as well as posttreatment dental care, are described...
  15. pmc Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma
    Hiromitsu Hatakeyama
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 5:e12702. 2010
    ....
  16. doi request reprint Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation
    Barbara A Murphy
    Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232 6307, USA
    Semin Radiat Oncol 19:35-42. 2009
    ....
  17. ncbi request reprint Systemic and global toxicities of head and neck treatment
    Barbara A Murphy
    Vanderbilt University Medical Center, Nashville, TN 37232 6307, USA
    Expert Rev Anticancer Ther 7:1043-53. 2007
    ..It is important for clinicians to be aware of these late effects in order to provide patients with appropriate support services and referrals. This paper examines the global and systemic effects of therapy...
  18. ncbi request reprint Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
    Douglas B Johnson
    Department of Medicine, Department of Cancer Biology, and Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Oncologist 19:616-22. 2014
    ..To determine the clinical impact of extensive genetic analysis, we reviewed our experience using a targeted NGS platform (FoundationOne) in advanced cancer patients...
  19. doi request reprint Patient enrollment onto clinical trials: the role of physician knowledge
    Justin R Gregg
    Department of Urologic Surgery, Vanderbilt University Medical Center, A 1302 Medical Center North, Nashville, TN, 37232 2765, USA
    J Cancer Educ 29:74-9. 2014
    ..Knowledge of clinical trials currently enrolling within a physician's specialty was associated with estimated patient enrollment, and may represent a correctable barrier to trial enrollment. ..
  20. pmc Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States
    Leora Horn
    Vanderbilt Ingram Cancer Center, Nashville, TN, USA
    J Clin Oncol 29:3932-8. 2011
    ....
  21. ncbi request reprint Organ preservation for cancer of the larynx: current indications and future directions
    Jill Gilbert
    Louisiana State University Health Sciences Center, Stanley S Scott Cancer Center, New Orleans, LA, USA
    Semin Radiat Oncol 14:167-77. 2004
    ..It remains to be seen whether such interventions can improve on the excellent locoregional control shown in the landmark Intergroup trial...
  22. ncbi request reprint Organ preservation trials for laryngeal cancer
    Jill Gilbert
    Louisiana State University, Health Sciences Center Stanley, C Scott Cancer Center, 433 Bolivar Street, New Orleans, LA 70112, USA
    Otolaryngol Clin North Am 35:1035-54, vi. 2002
    ....
  23. ncbi request reprint The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms
    Jennifer Bolt
    Stanley S Scott Cancer Center, LSU Health Sciences Center, New Orleans, LA, USA
    Oral Oncol 41:1013-20. 2005
    ..These findings indicate that molecular events resulting in inactivation of the ATM/p53 pathway are common in SCCHN and can arise by a number of distinct mechanisms...
  24. ncbi request reprint Outcome analysis of patients with squamous cell carcinoma of the head and neck and hepatitis C virus
    Jason Hunt
    Department of Otolaryngology and Biocommunication, Biostatistics Program, Hematology and Oncology Division at the Louisiana State University Health Sciences Center in New Orleans, 70112, USA
    Laryngoscope 115:1882-6. 2005
    ..A review of the literature reveals little information concerning this patient population. The objective of this study was to compare the outcome of SCCHN patients who have been exposed to HCV with naïve SCCHN patients...
  25. ncbi request reprint Prevalence and epidemiology of hepatitis C virus in patients with squamous cell carcinoma of the head and neck
    James Nobles
    Department of Otolaryngology and Biocommunication, Hematology and Oncology Division, Louisiana State University Health Sciences Center New Orleans, 533 Bolivar Street, New Orleans, LA 70112, U S A
    Laryngoscope 114:2119-22. 2004
    ..A review of the literature has revealed no published studies examining this association. The objective of this study was to determine the incidence and epidemiology of HCV infection in patients with SCCHN...
  26. ncbi request reprint The clinical application of targeting cancer through histone acetylation and hypomethylation
    Jill Gilbert
    Division of Oncology and Hematology, Stanley S Scott Cancer Center, Louisiana State University, New Orleans, Louisiana 70112, USA
    Clin Cancer Res 10:4589-96. 2004
    ..Reversal of these epigenetic processes and up-regulation of genes important to prevent or reverse the malignant phenotype has therefore become a new therapeutic target in cancer treatment...
  27. ncbi request reprint Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group
    Jill Gilbert
    Louisiana State University Medical Center, New Orleans, Louisiana, USA
    Head Neck 28:197-204. 2006
    ..The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies...
  28. ncbi request reprint A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
    Jill Gilbert
    Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA
    Invest New Drugs 24:499-508. 2006
    ..This was correlated with higher CNDAC Cmax and AUC values. No tumor responses were noted in this heavily pretreated population. However, given the ease of administration and tolerability, further investigation of this agent is warranted...
  29. ncbi request reprint Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 23:3906-11. 2005
    ..To characterize the pharmacokinetic behavior of 5-azacitidine (5-AC), a cytidine nucleoside analog, when given with phenylbutyrate, a histone deaceytlase inhibitor...